Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11516807 | 1.00 | RAB9A (0.50) | RAB9AALDH1A1POLBLMNAPRCP | |
| Hydrochloric Acid SCHEMBL7529821 | 0.77 | RAB9A (0.54) | RAB9AALDH1A1POLBLMNA | |
| SCHEMBL4004258 | 0.75 | RAB9A (0.56) | RAB9AALDH1A1POLBLMNA | |
| Hydrochloric Acid SCHEMBL7532420 | 0.73 | RAB9A (0.50) | RAB9AALDH1A1POLBLMNAAOC3 | |
| Hydrochloric Acid SCHEMBL21751204 | 0.73 | PRCP (0.40) | RAB9AALDH1A1POLBPRCP | |
| Hydrochloric Acid SCHEMBL7527276 | 0.72 | RAB9A (0.49) | RAB9AALDH1A1POLBLMNA | |
| SCHEMBL12312207 | 0.71 | PRCP (0.41) | RAB9AALDH1A1POLBPRCP | |
| SCHEMBL6420198 | 0.71 | LMNA (0.72) | RAB9AALDH1A1POLBLMNAPRCP | |
| SCHEMBL10297542 | 0.70 | RAB9A (0.39) | RAB9AALDH1A1POLBLMNAAOC3 | |
| Hydrochloric Acid SCHEMBL16038162 | 0.70 | RAB9A (0.50) | RAB9AALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040969-B2 | Compounds I | Benevolentai Cambridge Limited (GB) | 2021-06-22 | — | — | US | disclosed |
| CN-112851669-A | Pharmaceutical salt forms of semicarbazide-sensitive amine oxidase (SSAO) inhibitors | 博善人工智能剑桥有限公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3286189-B1 | CRYSTALLINE MESYLATE SALT AS SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME INHIBITOR | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2021-05-26 | — | — | EP | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| EP-3286190-B1 | PHARMACEUTICAL SALT FORMS OF AN INHIBITOR OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| US-10399973-B2 | Compounds I | Benevolentai Cambridge Limited (GB) | 2019-09-03 | — | — | US | disclosed |
| US-10369139-B2 | Crystalline compound as semicarbazide-sensitive amine oxidase (SSAO) enzyme inhibitor | Benevolentai Cambridge Limited (GB) | 2019-08-06 | — | — | US | disclosed |
| US-10316034-B2 | Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (SSAO) | Benevolentai Cambridge Limited (GB) | 2019-06-11 | — | — | US | disclosed |
| EP-3285767-B1 | TREATMENT OF PAIN | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2019-03-20 | — | — | EP | disclosed |
| US-20150218161-A1 | NEW COMPOUNDS I | PROXIMAGEN, LLC | 2015-08-06 | — | — | US | disclosed |
| US-9035066-B2 | Method of using 4,5,6,7-tetrahydroimidazo[4,5-C]pyridine compounds | PROXIMAGEN LIMITED (GB) | 2015-05-19 | — | — | US | disclosed |
| US-20140121219-A1 | New Compounds I | PROXIMAGEN LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| EP-2334672-B1 | 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine compounds as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| US-8569338-B2 | Methods of using 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine compounds | PROXIMAGEN LTD. (GB) | 2013-10-29 | — | — | US | disclosed |
| US-20120302583-A1 | New Compounds I | PROXIMAGEN LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8263616-B2 | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds | PROXIMAGEN LTD (GB) | 2012-09-11 | — | — | US | disclosed |
| US-20110207746-A1 | NEW COMPOUNDS I | PROXIMAGEN LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| EP-2334672-A1 | NEW COMPOUNDS I | Proximagen Limited (GB) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010031789-A1 | NEW COMPOUNDS I | BIOVITRUM AB (PUBL) (SE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | RAB9A 3287/4885ALDH1A1 477/4885POLB 950/4885 |
| US-10399973-B2 | Compounds I | SSB, SQLE, ALOX15B | RAB9A 3829/4885ALDH1A1 247/4885POLB 866/4885 |
| US-10369139-B2 | Crystalline compound as semicarbazide-sensitive amine oxidase (SSAO) enzyme inhibitor | PNPO, MAOA, AOC3 | RAB9A 4361/4885ALDH1A1 37/4885POLB 991/4885 |
| US-20110207746-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | RAB9A 3695/4885ALDH1A1 253/4885POLB 812/4885 |
| US-20120302583-A1 | New Compounds I | SSB, NFKBIA, NOD1 | RAB9A 3917/4885ALDH1A1 724/4885POLB 1251/4885 |
| US-11040969-B2 | Compounds I | SSB, SQLE, ALOX15B | RAB9A 3829/4885ALDH1A1 247/4885POLB 866/4885 |
| US-10316034-B2 | Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (SSAO) | SMOX, AOC3, DAO | RAB9A 4118/4885ALDH1A1 50/4885POLB 1612/4885 |
| US-20140121219-A1 | New Compounds I | SSB, NFKBIA, ALOX15B | RAB9A 3695/4885ALDH1A1 253/4885POLB 812/4885 |
| US-20150218161-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | RAB9A 3695/4885ALDH1A1 253/4885POLB 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.